STAAR Surgical Reports Progress on Japanese Application for Approval of Visian(TM) Implantable Collamer(R) Lens...(o market the Visian ICL and Visian Toric...),Health

Date:8/20/2009

o market the Visian ICL and Visian Toric ICL in Japan, or any other future approval by regulatory agencies; the possibility of favorable or adverse agency actions in the future; estimates of future sales of any product or any other financial items; the plans, strategies, and objectives of management for future operations or prospects for achieving such plans; our future performance; statements of belief; and any statements of assumptions underlying any of the foregoing.

These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties include the broad discretion of the PMDA in approving any medical device and the inherent uncertainty that new devices will be approved, the possibility that PMDA approval of ICL or TICL, if granted, may be subject to significant limitations or conditions, our limited capital resources and limited access to financing, the fact that our public accounting firm has expressed doubt about our ability to continue as a going concern in their opinion on our financial statements, the cost of defending pending litigation and satisfying judgment in the event of an adverse ruling, for which we have taken no reserve, the effect the global recession in reducing sales of products, especially products such as the ICL used in non-reimbursed elective procedures, the challenge of managing our foreign subsidiaries, the risk that sales of our newly introduced products may not restore profitability to our U.S. IOL product line, our ability to overcome negative publicity resulting from warning letters and other correspondence from the FDA Office of Compliance and to demonstrate to the agency that its past concerns have been resolved, the willingness of surgeons and patients to adopt a new product and procedure, and the po
'/>"/>

SOURCE STAAR Surgical Company Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine news :

1. STAAR Surgical Generates Cash From Operations During Second Quarter
2. STAAR Surgical to Present at BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York
3. Review of STAARs Application for the Visian(R) Toric Implantable Collamer(R) Lens by FDA to Resume
4. Review of STAARs Application for the Visian(R) Toric Implantable Collamer(R) Lens by FDA to Resume
5. STAAR Surgical Announces Second Quarter 2009 Earnings Release Date And Conference Call
6. Richard A. Meier Appointed to STAAR Surgical Board of Directors
7. STAAR Surgical Completes Common Stock Offering
8. STAAR Surgical Receives Japanese Clearance for the KS-Ni Preloaded IOL Injector System
9. STAAR Surgical Announces First Quarter 2009 Earnings Release Date and Conference Call
10. STAAR Surgical Reports 14% Fourth Quarter Revenue Growth
11. STAAR Surgical Forms Team of Leading Ophthalmic Surgeons to Study the Use of Collamer(R) Material for Accommodating Intraocular Lenses